Teleflex raises full‑year adjusted EPS outlook after Q3 results and OEM divestiture
Teleflex reported third‑quarter 2026 revenue of about $568 million, essentially flat year‑over‑year, and net income of $927 million driven by a gain from the sale of its OEM business. The company lifted its full‑year adjusted earnings per share guidance to a range of $7.50‑$7.75, up from the prior outlook. Management said the OEM sale, completed on August 3, generated $1.5 billion in net proceeds and produced a pretax gain of $1.0 billion, and that the remaining Acute Care and Interventional Urology divestiture is expected by year‑end 2026, though regulatory review could push closing into 2027.
Why it matters
The higher EPS guidance signals stronger profitability for the year, which may improve investor sentiment and affect the stock price. The $1.5 billion cash inflow from the OEM sale strengthens Teleflex’s balance sheet and could fund future growth initiatives.
Key facts
- 1Q3 2026 revenue was $567.78 million, a 0.1% increase versus the prior year quarter. tradingview.com
- 2Net income for the quarter was $927.43 million, a 326.8% rise from a loss of $408.89 million a year earlier. tradingview.com
- 3Adjusted EPS for the quarter was $2.63, beating estimates by 39.1%. finance.yahoo.com
- 4Full‑year adjusted EPS guidance was raised to $7.50‑$7.75. seekingalpha.com
- 5The OEM divestiture closed on August 3, delivering $1.5 billion in net proceeds and a pretax gain of $1.0 billion. tradingview.com
- 6The sale of the Acute Care and Interventional Urology business is expected to close by year‑end 2026, with possible extension into 2027. tradingview.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.